Statement of Changes in Beneficial Ownership (4)
April 01 2019 - 6:59PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Shak Steven
|
2. Issuer Name
and
Ticker or Trading Symbol
GENOMIC HEALTH INC
[
GHDX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
Chief Scientific Officer
|
(Last)
(First)
(Middle)
301 PENOBSCOT DRIVE
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/28/2019
|
(Street)
REDWOOD CITY, CA 94063
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
3/13/2019
|
|
G
|
V
|
2000
|
D
|
$0.00
|
333479
(1)
|
I
|
Held by the Shak Family Trust
|
Common Stock
(2)
|
3/28/2019
|
|
S
|
|
14620
|
D
|
$68.2119
(3)
(4)
|
318859
(1)
|
I
|
Held by the Shak Family Trust
|
Common Stock
(2)
|
3/28/2019
|
|
S
|
|
10272
|
D
|
$68.9717
(3)
(5)
|
308587
(1)
|
I
|
Held by the Shak Family Trust
|
Common Stock
(2)
|
3/28/2019
|
|
S
|
|
108
|
D
|
$69.665
(3)
(6)
|
308479
(1)
|
I
|
Held by the Shak Family Trust
|
Common Stock
(2)
|
3/29/2019
|
|
S
|
|
14372
|
D
|
$69.0314
(3)
(7)
|
294107
(1)
|
I
|
Held by the Shak Family Trust
|
Common Stock
(2)
|
3/29/2019
|
|
S
|
|
10528
|
D
|
$69.8425
(3)
(8)
|
283579
(1)
|
I
|
Held by the Shak Family Trust
|
Common Stock
(2)
|
3/29/2019
|
|
S
|
|
100
|
D
|
$70.49
(9)
|
283479
(1)
|
I
|
Held by the Shak Family Trust
|
Common Stock
(2)
|
4/1/2019
|
|
S
|
|
10521
|
D
|
$66.9418
(3)
(10)
|
272958
(1)
|
I
|
Held by the Shak Family Trust
|
Common Stock
(2)
|
4/1/2019
|
|
S
|
|
11279
|
D
|
$68.0461
(3)
(11)
|
261679
(1)
|
I
|
Held by the Shak Family Trust
|
Common Stock
(2)
|
4/1/2019
|
|
S
|
|
2100
|
D
|
$69.1161
(3)
(12)
|
259579
(1)
|
I
|
Held by the Shak Family Trust
|
Common Stock
(2)
|
4/1/2019
|
|
S
|
|
800
|
D
|
$69.8044
(3)
(13)
|
258779
(1)
|
I
|
Held by the Shak Family Trust
|
Common Stock
(2)
|
4/1/2019
|
|
S
|
|
300
|
D
|
$70.95
(9)
|
258479
(1)
|
I
|
Held by the Shak Family Trust
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Explanation of Responses:
|
(1)
|
Includes an aggregate of 9,210 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
|
(2)
|
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on November 30, 2018.
|
(3)
|
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
|
(4)
|
Represents weighted average sale price. Actual sale prices ranged from $67.54 to $68.52.
|
(5)
|
Represents weighted average sale price. Actual sale prices ranged from $68.60 to $69.42.
|
(6)
|
Represents weighted average sale price. Actual sale prices ranged from $69.65 to $69.74.
|
(7)
|
Represents weighted average sale price. Actual sale prices ranged from $68.47 to $69.44.
|
(8)
|
Represents weighted average sale price. Actual sale prices ranged from $69.48 to $70.34.
|
(9)
|
Represents actual sale price.
|
(10)
|
Represents weighted average sale price. Actual sale prices ranged from $66.54 to $67.51.
|
(11)
|
Represents weighted average sale price. Actual sale prices ranged from $67.55 to $68.53.
|
(12)
|
Represents weighted average sale price. Actual sale prices ranged from $68.60 to $69.58.
|
(13)
|
Represents weighted average sale price. Actual sale prices ranged from $69.62 to $70.38.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Shak Steven
301 PENOBSCOT DRIVE
REDWOOD CITY, CA 94063
|
|
|
Chief Scientific Officer
|
|
Signatures
|
/s/ Jason W. Radford, Attorney-in-fact
|
|
4/1/2019
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Genomic Health (NASDAQ:GHDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genomic Health (NASDAQ:GHDX)
Historical Stock Chart
From Sep 2023 to Sep 2024